MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Cabaletta Bio Operating Income 2011-2026 | CABA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Cabaletta Bio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -74.7 M | -54.1 M | -46.3 M | -33.8 M | -18.7 M | -6.19 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.19 M | -74.7 M | -39 M |
Quarterly Operating Income Cabaletta Bio
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.6 M | -45.9 M | - | -33 M | -30.3 M | -28 M | - | -18.7 M | -15.9 M | -17 M | - | -11.8 M | -13.1 M | -13 M | - | -11.6 M | -11.1 M | -9.71 M | - | -8.42 M | -8.19 M | -7.9 M | - | -5.03 M | -3.8 M | -3.99 M | - | -3.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.08 M | -46.6 M | -16.5 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.13 | -2.75 % | $ 2.54 B |  USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 163.18 | -1.92 % | $ 8.12 B | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.64 | -4.84 % | $ 1.09 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.37 | -4.12 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 23.82 | -0.25 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-23.4 M | $ 17.04 | -4.75 % | $ 818 M | USA |
 |
Champions Oncology
CSBR
|
4.55 M | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Daré Bioscience
DARE
|
-23.5 M | $ 1.59 | -1.27 % | $ 13.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-117 M | $ 21.94 | -5.66 % | $ 2.13 B | France |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-24.1 M | $ 25.4 | -5.44 % | $ 680 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-1.19 M | $ 17.58 | -3.14 % | $ 451 M | USA |
 |
Exelixis
EXEL
|
872 M | $ 40.7 | -0.8 % | $ 11.1 B | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Fennec Pharmaceuticals
FENC
|
-12.8 M | $ 7.91 | -3.77 % | $ 210 M | USA |
 |
Amicus Therapeutics
FOLD
|
32.8 M | $ 14.35 | -0.1 % | $ 4.43 B | USA |
 |
Galectin Therapeutics
GALT
|
-42.4 M | $ 2.95 | -3.59 % | $ 184 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Galapagos NV
GLPG
|
-166 M | $ 32.63 | -4.28 % | $ 2.69 B |  Belgium |
 |
Codexis
CDXS
|
-58.5 M | $ 0.98 | -3.85 % | $ 71.9 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-16 M | $ 26.25 | -4.16 % | $ 342 M | USA |
|
Galecto
GLTO
|
-39.9 M | $ 28.88 | -3.91 % | $ 767 M |  Danmark |
 |
Genmab A/S
GMAB
|
2.64 B | $ 27.42 | -7.52 % | $ 17.6 B | Danmark |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Gossamer Bio
GOSS
|
-184 M | $ 0.44 | 3.03 % | $ 67.2 M | USA |
 |
GeoVax Labs
GOVX
|
-26.7 M | $ 1.52 | -2.88 % | $ 2.76 M | USA |
 |
Grifols, S.A.
GRFS
|
595 M | $ 8.51 | -6.38 % | $ 6.83 B |  Spain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-160 M | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Halozyme Therapeutics
HALO
|
469 M | $ 68.8 | -1.5 % | $ 8.24 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-472 M | $ 28.35 | -2.91 % | $ 1.64 B | USA |
 |
Hoth Therapeutics
HOTH
|
-8.22 M | $ 0.98 | -3.92 % | $ 6.25 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |